Management of adolescent polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) is a common adolescent problem and its prevalence is rapidly increasing worldwide. Diagnosis of PCOS during this period is difficult due to the overlapping of the diagnostic criteria with normal pubertal development. Currently, the International evidence-based guideline (2018) has recommended using the Rotterdam criteria excluding the polycystic ovarian morphology component. However, the definition of each component depends on the age of the menarche. Similarly, the treatment options are not adequately evidence-based, rather adopted mostly from adult guidelines. Due to several concerns, a combined oral contraceptive pill-sparing combination therapy (spironolactone+pioglitazone+ metformin= SPIOMET) might be a promising therapeutic option. Duration of treatment is another uncertain issue. Prospective studies as well as well-designed randomized controlled trials are required for adequate management of adolescent PCOS.
J Assoc Clin Endocrinol Diabetol Bangladesh, July 2022; 1 (2): 55-64
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.